Best Biotech Stocks To Buy For 2019

tags:ARQL,AMGN,ALNY,BIIB,

Headlines about Intec Pharma (NASDAQ:NTEC) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.4513319646459 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Intec Pharma stock traded down $0.05 during mid-day trading on Thursday, reaching $4.63. The stock had a trading volume of 53,431 shares, compared to its average volume of 174,025. The stock has a market cap of $152.64 million, a price-to-earnings ratio of -2.81 and a beta of 1.25. Intec Pharma has a one year low of $4.35 and a one year high of $9.80.

Best Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Cory Renauer]

  What's behind these dramatic gains? Read on to find out.

  Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc.�(NASDAQ:MDGL) 205% $3.99 billion

  Data source: YCharts.

• [By Ethan Ryder]

  ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Best Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Chris Lange]

  Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Amgen (AMGN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By ]

  This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days," according to Real Money Pro columnist Bret Jensen.

Best Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Logan Wallace]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

• [By Joseph Griffin]

  BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

• [By Keith Speights]

  Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran�appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.�

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

• [By Shane Hupp]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

Best Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Cory Renauer]

  Biogen Inc.'s (NASDAQ:BIIB) Alzheimer's disease hopeful topped the list last year, but repeated failures with experimental drugs that attack the disease from a similar angle have all flopped. Despite the risk, EvaluatePharma estimates aducanumab's present value at�around�$8.4 billion and this figure will rise or fall dramatically when the company reads off results of ongoing pivotal trials, probably in early 2020.

• [By Todd Campbell]

  The acquisition of AveXis resulted in an $80 million milestone payment to Regenxbio in Q1 and an additional $100 million payment in June. If AVXS-101 wins an OK, Regenxbio will receive sales royalties in the mid single to low double digits, which could add up to hundreds of millions of dollars annually. For perspective,�Biogen's (NASDAQ:BIIB) Spinraza became the only FDA-approved treatment�for SMA in late 2016, and its sales are already tracking at an annualized pace of over $1.2 billion, even though only 40% of patients see an improvement on it.

• [By Cory Renauer]

  Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),�Celgene Corporation (NASDAQ:CELG), and�Gilead Sciences Inc.�(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.�

Facebook, Inc. Common Stock (FB) Given New $242.00 Price Target at Stifel Nicolaus

Facebook, Inc. Common Stock (NASDAQ:FB) had its price objective boosted by Stifel Nicolaus from $202.00 to $242.00 in a report issued on Friday, MarketBeat.com reports. Stifel Nicolaus currently has a buy rating on the social networking company’s stock.

Other equities research analysts also recently issued reports about the stock. Argus increased their price objective on shares of Facebook, Inc. Common Stock to $214.00 in a research note on Wednesday, April 11th. JPMorgan Chase & Co. reiterated a buy rating and set a $242.00 price objective on shares of Facebook, Inc. Common Stock in a research note on Tuesday, April 10th. Jefferies Financial Group reiterated a buy rating and set a $215.00 price objective on shares of Facebook, Inc. Common Stock in a research note on Monday, April 9th. Wells Fargo & Co reiterated a buy rating and set a $230.00 price objective on shares of Facebook, Inc. Common Stock in a research note on Thursday, April 5th. Finally, Morningstar set a $198.00 price objective on shares of Facebook, Inc. Common Stock and gave the stock a buy rating in a research note on Monday, March 26th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, forty-three have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $223.75.

Get Facebook Inc. Common Stock alerts:

Facebook, Inc. Common Stock traded up $1.85, reaching $209.94, during mid-day trading on Friday, MarketBeat.com reports. 16,143,832 shares of the company’s stock were exchanged, compared to its average volume of 15,226,154. Facebook, Inc. Common Stock has a one year low of $149.02 and a one year high of $211.50. The firm has a market cap of $604.50 billion, a price-to-earnings ratio of 34.08, a P/E/G ratio of 1.10 and a beta of 0.85.

Facebook, Inc. Common Stock (NASDAQ:FB) last released its quarterly earnings results on Wednesday, April 25th. The social networking company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.44. Facebook, Inc. Common Stock had a net margin of 40.03% and a return on equity of 27.74%. The business had revenue of $11.97 billion for the quarter, compared to analyst estimates of $11.41 billion. During the same period last year, the firm earned $1.04 earnings per share. Facebook, Inc. Common Stock’s revenue for the quarter was up 49.0% compared to the same quarter last year. analysts anticipate that Facebook, Inc. Common Stock will post 7.72 EPS for the current fiscal year.

In related news, VP David B. Fischer sold 5,138 shares of Facebook, Inc. Common Stock stock in a transaction that occurred on Wednesday, April 25th. The shares were sold at an average price of $160.07, for a total transaction of $822,439.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Colin Stretch sold 750 shares of Facebook, Inc. Common Stock stock in a transaction that occurred on Wednesday, July 18th. The stock was sold at an average price of $210.00, for a total transaction of $157,500.00. Following the sale, the vice president now owns 88,615 shares in the company, valued at $18,609,150. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,033,116 shares of company stock worth $3,041,961,441. 17.23% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in shares of Facebook, Inc. Common Stock by 2.0% in the 1st quarter. BlackRock Inc. now owns 149,137,226 shares of the social networking company’s stock valued at $23,830,637,000 after acquiring an additional 2,966,437 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Facebook, Inc. Common Stock by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 25,433,759 shares of the social networking company’s stock valued at $4,478,724,000 after acquiring an additional 1,010,306 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Facebook, Inc. Common Stock by 3.1% in the 4th quarter. Alliancebernstein L.P. now owns 15,125,319 shares of the social networking company’s stock valued at $2,669,014,000 after acquiring an additional 458,048 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of Facebook, Inc. Common Stock by 0.5% in the 1st quarter. Loomis Sayles & Co. L P now owns 12,937,287 shares of the social networking company’s stock valued at $2,067,249,000 after acquiring an additional 58,561 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Facebook, Inc. Common Stock by 4.6% in the 4th quarter. UBS Asset Management Americas Inc. now owns 12,587,578 shares of the social networking company’s stock valued at $2,221,204,000 after acquiring an additional 558,184 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Facebook, Inc. Common Stock Company Profile

Facebook, Inc provides various products to connect and share through mobile devices, personal computers, and other surfaces worldwide. Its products include Facebook Website and mobile application that enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Instagram, a community for sharing visual stories through photos, videos, and direct messages; Messenger, a messaging application to communicate with other people, groups, and businesses across various platforms and devices; and WhatsApp, a mobile messaging application.

Featured Story: Book Value Per Share �� BVPS

'Papa John' hires Harvey Weinstein's lawyer

LOUISVILLE -- Papa John's founder John Schnatter has hired an attorney who's representing disgraced movie executive Harvey Weinstein against the company he founded.

Los Angeles trial lawyer Patricia Glaser had been enlisted by Schnatter, who said in a letter to the company Saturday�that he will�fight his removal as the Papa John's chairman and that he's being maligned by reports of his use of a racial slur during a media training session in May.�

Schnatter and Glaser request that the Papa John's board form a special committee to review the facts surrounding the incident, according to letters obtained by the Louisville�Courier Journal.�

Glaser is a well-known defense attorney who Weinstein hired to negotiate with�The Weinstein Co., after it terminated the�ex-Hollywood mogul's employment related to dozens of misconduct allegations.�

FacebookTwitterGoogle+LinkedIn'Papa John' Schnatter through the years FullscreenPost to FacebookPosted!

A link has been posted to your Facebook feed.

Papa John's founder John Schnatter. December 19, 2012  Michael Clevenger/The Courier-JoFullscreen John Schnatter of Papa John's Pizza  , Larry Spitzer/Courier Journal Fullscreen Papa John's founder John Schnatter chats in the hall after a seminar speech at the Galt East in Louisville.- Sept. 24, 1996  Paul Schaumann/Courier JournalFullscreen John 'Papa John' Schnatter.  file photoFullscreen Papa John's International marked the opening of its 3,000th store by giving away fresh tomatoes and pizza slices in New York.- -CEO Nigel Travis and Chairman John Schnatter also took part in a ceremonial opening of Nasdaq Stock Market trading as part of the festivities, and the company donated $20,000 and fresh produce to City Harvest, an organization that feeds the hungry in New York.  Copyright 2005 The Courier Journal, No Courier JournalFullscreen John Schnatter, founder of Papa John's Pizza stands on a staircase in the lobby of the company's headquarters. By Pat McDonogh, The Courier-Journal. Jan. 26, 2016.  By Pat McDonogh/The Courier JournalFullscreen Papa John's founder John Schnatter tastes a spoonful of pizza sauce May 20, 1997.  Michael ClevengerFullscreen Papa John's Pizza founder John Schnatter told Anchorage residents at a special meeting that he plans to build a walking trail from the center of the city to E.P. "Tom" Sawyer State Park, regardless of whether the city sells him the five-acre Bellewood property. Photo by Chris Otts April 2007. *date of photo is unknown  Chris Otts/The Courier JournalFullscreen John Schnatter, (right) Founder of Papa John's Pizza, talked with Tracy Proffit (left) Chef Douglas Bond (left center) and Terry Lewis manager of the campus restaurant in Louisville. -March 28, 2009  Chris Hall/The Courier JournalFullscreen John Schnatter received a national award for the two-mile public trail Schnatter built on his property in Anchorage earlier this year. - Nov. 25, 2008.  Kylene Lloyd/The Courier JournalFullscreen John Schnatter received a national award for the two-mile public trail Schnatter built on his property in Anchorage earlier this year. - Nov. 25, 2008.  KYLENE LLOYDFullscreen Papa John's founder, John Schnatter, recovered the 1971 Camaro he sold years ago to support his business. - Aug. 25, 2009  Michael Hayman/The Courier JournalFullscreen Papa John's CEO John Schnatter, left, and Dallas Cowboys owner Jerry Jones announced a joint venture yesterday at the Cowboys' camp. - Aug. 3, 2004, in Oxnard, Calif. Jones announced a joint venture in the Dallas, Austin and Waco, Texas markets with Papa John's International, Inc. (AP Photo/Tony Gutierrez)  Tony Gutierrez, Copyright 2004 The Courier-Journal;NO COURIER-JOURNALFullscreen Papa John's founder and CEO John Schnatter spoke to shareholders during the annual meeting.Mary Ann Lyons, May 20, 1999  Mary Ann Lyons, Copyright 1999 The Courier-Journal;YES COURIER-JOURNALFullscreen Papa John's Founder, Chairman and CEO John Schnatter gets a kick out of seeing his image on the NASDAQ tower in New York's Times Square, Friday, Sept. 14, 2012, while celebrating the opening of the brand's 4,000th global restaurant.  Diane Bondareff/AP ImageFullscreen John Schnatter, founder of Papa John's Pizza. - Oct. 2, 2017  Sam Upshaw Jr./The Courier Journal Fullscreen Louisville's interim AD talks with University of Louisville board of trustees member John Schnatter at the Cardinals game against Bellarmine. - Nov. 11, 2017  Scott Utterback/The Courier Journal Fullscreen In this file photo from 2016, John Schnatter placed a pie in the oven at the headquarters' kitchen. - Jan. 26, 2016.  Pat McDonogh/The Courier JournalFullscreen In this file photo, John Schnatter, founder of Papa John's Pizza, is seen making a pizza in the kitchen of his company's headquarters. - Jan. 26, 2016.  Pat McDonogh/The Courier JournalFullscreen Papa John's founder John Schnatter salutes another board member before the start of the Wednesday meeting to decide Tom Jurich's fate at the University of Louisville. - Oct. 18, 2017  Matt Stone/The Courier JournalFullscreen John Schnatter, left, CEO of Papa John's Pizza, arrives for a UofL for Board of Trustees meeting escorted by Buddy Dumeyer outside Grawemeyer Hall. - Oct. 2, 2017  Sam Upshaw Jr./The Courier JournalFullscreen John Schnatter, founder of Papa John's Pizza  The Courier Journal file photoFullscreen John Schnatter, founder of Papa John's Pizza. -June 19, 2017  Provided by Delta DentalFullscreen John Schnatter, board member at the University of Louisville Foundation, during the first meeting since an audit blasted the organization.  Matt Stone/The Courier JournalFullscreen Papa John's Pizza founder John Schnatter talks with other board members after the University of Louisville Wednesday. Schnatter did not speak during Wednesday's meeting. Previously he brought up concerns with the University of Louisivlle athletic department. April, 26, 2017.  Matt Stone/CJFullscreen John Schnatter speaks during a press conference at the Louisville Zoo on Thursday morning. Thanks to a $1 million gift from the John H. Schnatter Family Foundation, the zoo's Leadership Campaign exceeded it's goal of $10.4 million for a final raised amount of $11.44 million. -Feb.9, 2017  Michael Clevenger/The Courier JournalFullscreen John Schnatter looks over renderings of a new exhibit on Thursday morning at the Louisville Zoo with Zoo Director John Walczak. Thanks to a $1 million gift from the John H. Schnatter Family Foundation, the zoo's Leadership Campaign exceeded it's goal of $10.4 million for a final raised amount of $11.44 million. -Feb. 9, 2017  Michael Clevenger/The Courier JournalFullscreen John Schnatter speaks during a press conference at the Louisville Zoo on Thursday morning. Thanks to a $1 million gift from the John H. Schnatter Family Foundation, the zoo's Leadership Campaign exceeded it's goal of $10.4 million for a final raised amount of $11.44 million. -Feb. 9, 2017  Michael Clevenger/The Courier JournalFullscreen Papa John's founder John Schnatter laughs aloud during an interview with Alli Truttmann on Wednesday night at the Palace Theatre. 1/25/17  Marty Pearl/Special to the Courier JournalFullscreen Papa John��s founder John Schnatter, shown at an unrelated event, attended an employee��s funeral. -Aug. 27, 2007  David Harpe/Special to the Courier-JournalFullscreenInterested in this topic? You may also want to view these photo galleries:Replay1 of 302 of 303 of 304 of 305 of 306 of 307 of 308 of 309 of 3010 of 3011 of 3012 of 3013 of 3014 of 3015 of 3016 of 3017 of 3018 of 3019 of 3020 of 3021 of 3022 of 3023 of 3024 of 3025 of 3026 of 3027 of 3028 of 3029 of 3030 of 30AutoplayShow ThumbnailsShow CaptionsLast SlideNext Slide

Glaser is not representing Weinstein in charges of rape and criminal sexual�acts, for which he has pleaded not guilty. At�least 85 women have accused Weinstein of inappropriate to criminal behavior.�

In his letter, Schnatter said it was a mistake on his part to resign his chairmanship of the pizza empire he created and is now questioning why his company's board of directors didn't investigate his use of a racial slur before it moved�to oust him.�

��The board asked me to step down as chairman without apparently doing any investigation. I agreed, though today I believe it was a mistake to do so,���Schnatter wrote to the board of directors in a letter�Saturday. ��I will not allow either my good name or the good name of the company I founded and love to be unfairly tainted.��

More: Papa John's John Schnatter should have admitted racial bias and learned to do better

More: How rich is 'Papa John' Schnatter? You'll be amazed

More: Aston Martin's flying car concept is fit for James Bond

�

Schnatter resigned last week as chairman of the board of directors after he admitted to using a racial slur in a role-playing exercise with the pizza chain's marketing contractor. The fall out has been swift and enormous.�

He was forced off the board of trustees at the University of Louisville where the new president also made the decision last Friday to remove his name from the school's football stadium.�

Papa Johns International also�is removing his image from marketing materials.

The chain, which Schnatter founded in 1984 and took public less than a decade later, has kicked him out of the corporation's East Louisville offices and ordered him to stop talking with the media.�

Although he apologized for using the N-word during that May conference call, he's since been combative in interviews, insisting in an interview with WHAS radio host Terry Meiners last Friday that the marketing contract forced him in to using "that vocabulary" and leaked it to the media later.

The Wall Street Journal said that Schnatter says in his letter to the board that he was asked during the media training whether he is racist, and answered ��no ... I then said something on the order of, (KFC founder) Colonel (Harland) Sanders used the word ��N,�� (I actually used the word), that I would never use that word, and Papa John��s doesn��t use that word.���

�